Furthermore, this study provides new insight into the molecular mechanism of the anti-tumor selectivity of HDACIs and suggests that HDACIs might be a more effective clinical target in tumors with high c-Jun/Fra-1 activity mediated by MKK7 and Raf1. This evidence concerns the gene RAF1 and neoplasm.